Keros Therapeutics (NASDAQ:KROS) Research Coverage Started at Guggenheim

Guggenheim assumed coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a research note released on Monday, MarketBeat reports. The firm issued a buy rating and a $96.00 price target on the stock.

Other equities analysts also recently issued research reports about the company. Bank of America cut their price objective on Keros Therapeutics from $81.00 to $76.00 and set a buy rating on the stock in a research report on Thursday, September 12th. Truist Financial reaffirmed a buy rating and issued a $100.00 price target on shares of Keros Therapeutics in a research note on Tuesday, June 18th. Oppenheimer assumed coverage on shares of Keros Therapeutics in a research report on Tuesday, June 25th. They issued an outperform rating and a $102.00 price objective for the company. Finally, HC Wainwright reaffirmed a buy rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of Buy and an average price target of $90.63.

Keros Therapeutics Stock Up 1.5 %

KROS stock opened at $56.45 on Monday. Keros Therapeutics has a twelve month low of $27.02 and a twelve month high of $73.00. The stock has a market capitalization of $2.12 billion, a price-to-earnings ratio of -11.02 and a beta of 1.22. The firm’s fifty day simple moving average is $49.67 and its two-hundred day simple moving average is $52.76.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. The firm had revenue of $0.04 million during the quarter. During the same quarter in the prior year, the business earned ($1.27) earnings per share. As a group, equities research analysts expect that Keros Therapeutics will post -4.88 EPS for the current year.

Insider Buying and Selling

In other news, Director Carl L. Gordon sold 250,000 shares of Keros Therapeutics stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the transaction, the director now directly owns 119,522 shares in the company, valued at approximately $5,260,163.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 22.90% of the stock is currently owned by insiders.

Institutional Trading of Keros Therapeutics

Several hedge funds have recently modified their holdings of KROS. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Keros Therapeutics during the 2nd quarter worth approximately $128,000. Ameritas Investment Partners Inc. lifted its holdings in shares of Keros Therapeutics by 14.5% during the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after purchasing an additional 324 shares during the last quarter. Quest Partners LLC lifted its holdings in shares of Keros Therapeutics by 23,945.0% during the 2nd quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock valued at $220,000 after purchasing an additional 4,789 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Keros Therapeutics in the 2nd quarter worth $228,000. Finally, Bayesian Capital Management LP purchased a new position in Keros Therapeutics during the 1st quarter worth $267,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.